Brief: Eagle Pharmaceuticals Reports Fourth Quarter And Full Year 2021 Results
07/03/2022 12:31
March 7 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR
2021
RESULTS
* SEES Q1 ADJUSTED NON-GAAP EARNINGS PER SHARE $3.80 TO
$4.10
* SEES Q1 EARNINGS PER SHARE $4.00
* Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.85
* Q4 LOSS PER SHARE $0.48
* SEES Q1 REVENUE $120 MILLION TO $130 MILLION
* Q4 REVENUE $42.3 MILLION
Source text for Eikon: ID:nGNX4BfkV7
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq